ValuEngine upgraded shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) from a sell rating to a hold rating in a report issued on Monday morning.
Several other analysts have also recently issued reports on the stock. Cantor Fitzgerald restated a buy rating and set a $28.00 target price on shares of Aquinox Pharmaceuticals in a research report on Sunday, February 11th. Zacks Investment Research cut shares of Aquinox Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, January 12th. Canaccord Genuity set a $22.00 target price on shares of Aquinox Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, December 19th. Guggenheim initiated coverage on shares of Aquinox Pharmaceuticals in a research report on Thursday, February 8th. They set a buy rating and a $26.00 target price on the stock. Finally, BidaskClub upgraded shares of Aquinox Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, February 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. Aquinox Pharmaceuticals has a consensus rating of Hold and a consensus target price of $22.80.
AQXP stock traded down $0.14 during mid-day trading on Monday, hitting $13.77. The company had a trading volume of 22,235 shares, compared to its average volume of 110,814. Aquinox Pharmaceuticals has a 12-month low of $10.02 and a 12-month high of $16.90.
A number of large investors have recently modified their holdings of AQXP. Northern Trust Corp grew its holdings in Aquinox Pharmaceuticals by 3.3% during the 2nd quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock valued at $1,171,000 after purchasing an additional 2,691 shares during the last quarter. Citadel Advisors LLC bought a new position in Aquinox Pharmaceuticals during the 3rd quarter valued at about $194,000. University of Notre Dame DU Lac grew its holdings in Aquinox Pharmaceuticals by 11.1% during the 3rd quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock valued at $2,700,000 after purchasing an additional 19,066 shares during the last quarter. Alyeska Investment Group L.P. grew its holdings in Aquinox Pharmaceuticals by 1.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 282,569 shares of the company’s stock valued at $4,010,000 after purchasing an additional 5,046 shares during the last quarter. Finally, D.A. Davidson & CO. grew its holdings in Aquinox Pharmaceuticals by 42.8% during the 4th quarter. D.A. Davidson & CO. now owns 14,350 shares of the company’s stock valued at $169,000 after purchasing an additional 4,300 shares during the last quarter. Institutional investors own 91.45% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Aquinox Pharmaceuticals (AQXP) Raised to Hold at ValuEngine” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3335203/aquinox-pharmaceuticals-aqxp-raised-to-hold-at-valuengine.html.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.